Literature DB >> 31858523

Hepatocellular carcinoma in non-alcoholic fatty liver disease (NAFLD) - pathological evidence for a predominance of steatohepatitic inflammatory non-proliferative subtype.

Priscila B de Campos1, Claudia P Oliveira2,3, José T Stefano3, Sebastião N Martins-Filho4, Aline L Chagas5, Paulo Herman5, Luiz C D'Albuquerque5, Mário R Alvares-da-Silva6, Adhemar Longatto-Filho4,7,8, Flair J Carrilho1,3, Venancio A F Alves1,4.   

Abstract

OBJECTIVES: This study evaluated clinical and pathological aspects of patients with hepatocellular carcinoma (HCC) secondary to non-alcoholic fatty liver disease (NAFLD) and related these factors to immunohistochemical markers representative of the proliferative class.
METHODS: We evaluated 35 HCC nodules from 21 patients diagnosed with NAFLD undergoing liver resection (n=12) or liver transplantation (n=8) or both (n=1). Demographic, clinical and biochemical data were compared to histological features and to immunohistochemical reactivity for K19 and Ki-67.
RESULTS: Cirrhosis was present in 58% of patients. Ages ranged from 50 to 77 years. Sixteen patients (76%) were male and had type 2 diabetes mellitus, 81% had arterial hypertension, and 90% had BMI above 25 kg/m². Alpha-fetoprotein levels were normal in 62% of patients. Twenty-five (70%) nodules were diagnosed as "steatohepatitic HCC". Only 32% of the nodules presented high levels of Ki-67 (>10%) and/or K19 (>5%), although 63% were poorly differentiated (G.3/G.4) according to Edmondson & Steiner grading system. K19 positivity (>5%) was associated with higher degree of intratumoral inflammation (G.2/G.3), and with fibrosis, both at the center of the tumor and at the tumor front, whereas Ki-67 positivity (>10%) was associated with ballooning of neoplastic cells and occurred in more than 70% in non-cirrhotic patients.
CONCLUSION: NAFLD-related HCC was found in non-cirrhotic patients in 42% of cases, alpha-fetoprotein level was normal in 63% and "steatohepatitic HCC" was the predominant histological type. Immunoexpression of K19 and/or Ki-67 occurred in 32% of the nodules and were associated with intratumoral inflammation and ballooning, suggesting that HCC in MtS may be preferentially "an inflammatory, non-proliferative subtype of HCC".

Entities:  

Mesh:

Year:  2019        PMID: 31858523     DOI: 10.14670/HH-18-194

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  38 in total

Review 1.  The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.

Authors:  Vasilios G Athyros; Theodore K Alexandrides; Helen Bilianou; Evangelos Cholongitas; Michael Doumas; Emmanuel S Ganotakis; John Goudevenos; Moses S Elisaf; Georgios Germanidis; Olga Giouleme; Asterios Karagiannis; Charalambos Karvounis; Niki Katsiki; Vasilios Kotsis; Jannis Kountouras; Evangelos Liberopoulos; Christos Pitsavos; Stergios Polyzos; Loukianos S Rallidis; Dimitrios Richter; Apostolos G Tsapas; Alexandros D Tselepis; Konstantinos Tsioufis; Konstantinos Tziomalos; Themistoklis Tzotzas; Themistoklis G Vasiliadis; Charalambos Vlachopoulos; Dimitri P Mikhailidis; Christos Mantzoros
Journal:  Metabolism       Date:  2017-03-04       Impact factor: 8.694

2.  Prognostic Value of Ki67 Expression for Patients with Surgically Resected Hepatocellular Carcinoma: Perspectives from a High Incidence Area.

Authors:  Kai Bai; Yi Cao; Qiaojia Huang; Yi Jiang; Lizhi Lv
Journal:  Clin Lab       Date:  2017-02-01       Impact factor: 1.138

3.  Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients?

Authors:  A L Chagas; L O O Kikuchi; C P M S Oliveira; D C P Vezozzo; E S Mello; A C Oliveira; L C Cella; P Herman; T Bachella; S H Caldwell; V A F Alves; F J Carrilho
Journal:  Braz J Med Biol Res       Date:  2009-09-04       Impact factor: 2.590

Review 4.  Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma.

Authors:  Jordi Bruix; Maria Reig; Morris Sherman
Journal:  Gastroenterology       Date:  2016-01-12       Impact factor: 22.682

Review 5.  Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD.

Authors:  Lucia Carulli; Mauro Maurantonio; Lionel Hebbard; Enrica Baldelli; Paola Loria; Jacob George
Journal:  Curr Pharm Des       Date:  2013       Impact factor: 3.116

6.  Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study.

Authors:  Jacob Alexander; Michael Torbenson; Tsung-Teh Wu; Matthew M Yeh
Journal:  J Gastroenterol Hepatol       Date:  2013-05       Impact factor: 4.029

Review 7.  Non-alcoholic steatohepatitis and cancer.

Authors:  E Bugianesi
Journal:  Clin Liver Dis       Date:  2007-02       Impact factor: 6.126

8.  DNA topoisomerase IIα and Ki67 are prognostic factors in patients with hepatocellular carcinoma.

Authors:  Yi Cao; Ruisheng Ke; Shaohu Wang; Xu Zhu; Jianwei Chen; Chao Huang; Yi Jiang; Lizhi Lv
Journal:  Oncol Lett       Date:  2017-04-06       Impact factor: 2.967

9.  Hepatocellular carcinoma is the most common liver-related complication in patients with histopathologically-confirmed NAFLD in Japan.

Authors:  Norio Akuta; Yusuke Kawamura; Yasuji Arase; Satoshi Saitoh; Shunichiro Fujiyama; Hitomi Sezaki; Tetsuya Hosaka; Masahiro Kobayashi; Mariko Kobayashi; Yoshiyuki Suzuki; Fumitaka Suzuki; Kenji Ikeda; Hiromitsu Kumada
Journal:  BMC Gastroenterol       Date:  2018-11-06       Impact factor: 3.067

10.  Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma.

Authors: 
Journal:  Cell       Date:  2017-06-15       Impact factor: 66.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.